Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
opolimogene capmilisbac
- Development stage
- Discontinued
- Lead developer
- Janssen Biotech
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Opolimogene capmilisbac (JNJ-64041809, also known as ADU-741) is an investigational live attenuated double-deleted (LADD) *Listeria monocytogenes*-based therapeutic cancer vaccine. It was developed to target metastatic castration-resistant prostate cancer (mCRPC). The therapy encodes and expresses four antigens relevant to prostate cancer, aiming to stimulate the immune system against tumor cells. Upon intravenous administration, the engineered bacteria are taken up by antigen-presenting cells, leading to activation of both innate and adaptive immune responses. Clinical studies showed manageable safety but limited antigen-specific immune responses that did not translate into objective clinical benefit. Development was discontinued after early-phase trials.
- Other names
- opolimogene capmilisbac
02
Targets
ErbB (EGFR family)
Beyond the preview
Go deeper on opolimogene capmilisbac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on opolimogene capmilisbac.